Guggenheim Raises PT on Eli Lilly (LLY) Amid Several Acquisition Deals [Yahoo! Finance]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Yahoo! Finance
Guggenheim Raises PT on Eli Lilly (LLY) Amid Several Acquisition Deals Pixabay/Public Domain As of April 23, 2026, a majority of analysts covering the stock have a Buy rating on it; that is, 77% of all covering analysts, and their consensus price target of $1,250 suggests Eli Lilly and Company (NYSE:LLY) could climb around 40% from current levels. That confidence was on display the same day, when Guggenheim raised its price target on Eli Lilly and Company (NYSE:LLY) to $1,183 from $1,163 and held on to its “Buy” rating, just ahead of the company's first quarter results. The firm updated its model to account for a disclosed $584 million charge tied to in-process research and development, equal to $0.52 per share, folding in the cost of Lilly's recently announced acquisitions of Centessa Pharmaceuticals and Kelonia Therapeutics. Even with those charges weighing on near-term earnings, Guggenheim kept a constructive view on Eli Lilly and Company (NYSE:LLY). The acquisitions the
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Eli Lilly Shares Jump as Mounjaro, Zepbound Fuel Massive Growth [Yahoo! Finance]Yahoo! Finance
- Eli Lilly blows past quarterly estimates, hikes outlook as Zepbound and Mounjaro sales skyrocket [MSNBC.com]MSNBC.com
- Eli Lilly CEO David Ricks on Q1 results, Zepbound-Mounjaro sales growth and launch of Foundayo pill [CNBC]CNBC
- Watch CNBC's full interview with Eli Lilly CEO David Ricks [CNBC]CNBC
- Eli Lilly (NYSE:LLY) Delivers Strong Q1 CY2026 Numbers, Stock Soars [Yahoo! Finance]Yahoo! Finance
LLY
Earnings
- 4/30/26 - Beat
LLY
Sec Filings
- 4/30/26 - Form 8-K
- 4/29/26 - Form PX14A6G
- 4/21/26 - Form 4
- LLY's page on the SEC website